Why the study?
Does paliperidone have torsadogenic potential compared to risperidone in an acute atrioventricular block rabbit model?
Does paliperidone have torsadogenic potential compared to risperidone in an acute atrioventricular block rabbit model?
Paliperidone exhibits torsadogenic potential at supra-therapeutic doses, though its potency appears equal to or slightly less than that of risperidone.
Answers are grounded in this paper and cite their sources.
May support QT monitoring at higher paliperidone doses; leaves open clinical proarrhythmic relevance.
We assessed electrophysiological effects of an atypical antipsychotic drug paliperidone in acute atrioventricular block rabbits. Intravenous administration of paliperidone at a clinically relevant dose (0.06 mg/kg) hardly affected the QT interval or monophasic action potential (MAP) duration, and the higher doses (0.6 and 6 mg/kg) prolonged the QT interval and MAP duration. Meanwhile, premature ventricular contractions with R on T phenomenon were observed in 3 out of 6 animals at the middle dose, and torsades de pointes (TdP) episodes were detected in 2 out of 6 animals at the high dose. Intravenous administration of its chemically related compound risperidone at a clinically relevant dose (0.03 mg/kg) hardly affected the electrophysiological parameters, and the higher doses (0.3 and 3 mg/kg) prolonged the QT interval and MAP duration. Meanwhile, the premature ventricular contractions with R on T were observed in 2 out of 6 animals at the middle dose, and TdP episodes were detected in 4 out of 6 animals at the high dose. These results suggest that paliperidone showed torsadogenic potential at supra-therapeutic doses, whose potency can be estimated to be equal or slightly subordinate in comparison with that of risperidone.
No takes yet. Share an insight, caveat, or question.
Hagiwara et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: